GHRH and non-small cell lung carcinoma: In vitro studies using human lung cancer cell lines, including small-cell lung cancer (SCLC) H446 and non-small-cell lung cancer (NSCLC) HCC827 and H460 cells, demonstrated that GHRH agonist MR-409 exerted significant agonistic activity, inhibiting tumor growth [50].